Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ADVM Stock Forecast 2026-2027
$4.36
Current Price
$96.26M
Market Cap
Buy 2
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to ADVM Price Targets
+26.1%
To High Target of $5.50
+14.7%
To Median Target of $5.00
-8.3%
To Low Target of $4.00
ADVM Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+65.8%
1 Year Change
0.0%
Year-to-Date Change
-28.8%
From 52W High of $6.12
+144.9%
From 52W Low of $1.78
📊 TOP ANALYST CALLS
Did ADVM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Adverum is one of their latest high-conviction picks.
Latest ADVM Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, ADVM has a neutral consensus with a median price target of $5.00 (ranging from $4.00 to $5.50). The overall analyst rating is Buy (7.6/10). Currently trading at $4.36, the median forecast implies a 14.7% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Lisa Walter at RBC Capital, suggesting a 8.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADVM Analyst Ratings
2
Buy
3
Hold
0
Sell
ADVM Price Target Range
Low
$4.00
Average
$5.00
High
$5.50
Current: $4.36
Latest ADVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADVM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $5.00 |
| Oct 28, 2025 | RBC Capital | Lisa Walter | Sector Perform | Maintains | $4.00 |
| Sep 23, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Aug 13, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Jun 26, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $12.00 |
| May 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| May 15, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| May 15, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $4.00 |
| Apr 17, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Apr 16, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Apr 16, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $5.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Nov 5, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $10.00 |
| Aug 14, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $40.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $12.00 |
| Aug 13, 2024 | HC Wainwright& Co. | Buy | Reiterates | $N/A | |
| Jul 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $40.00 |
| Jun 25, 2024 | Oppenheimer | Francois Brisebois | Outperform | Initiates | $25.00 |
| May 15, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $60.00 |
Adverum Biotechnologies, Inc. (ADVM) Competitors
The following stocks are similar to Adverum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adverum Biotechnologies, Inc. (ADVM) Financial Data
Adverum Biotechnologies, Inc. has a market capitalization of $96.26M with a P/E ratio of -0.7x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -13,915.9% and return on equity of -417.8%.
Valuation Metrics
Market Cap
$96.26M
Enterprise Value
$159.14M
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
96.3x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-13,915.9%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+27.1%
Current Ratio
0.6x
Debt/Equity
-1.6x
ROE
-417.8%
ROA
-76.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Adverum Biotechnologies, Inc. (ADVM) Business Model
About Adverum Biotechnologies, Inc.
What They Do
Develops gene therapies for ocular diseases.
Business Model
The company focuses on creating durable, single-administration gene therapies to treat serious ocular conditions. By utilizing an innovative vector platform for therapeutic gene delivery, it aims to address unmet medical needs in patients suffering from retinal diseases, thereby generating revenue through the development and commercialization of its therapeutic products.
Additional Information
Adverum collaborates with research institutions and industry experts to advance its gene therapy solutions. Based in Redwood City, California, the company is positioned at the forefront of biotechnology and healthcare, with a commitment to transforming the landscape of ophthalmic care and influencing the future of regenerative medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
155
CEO
Dr. Laurent Fischer M.D.
Country
United States
IPO Year
2014
Website
adverum.comAdverum Biotechnologies, Inc. (ADVM) Latest News & Analysis
Latest News
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
7 months ago
Quick Summary
Eli Lilly's subsidiary, Flying Tigers Acquisition Corp, completed a tender offer for Adverum Biotechnologies at $3.56 per share, plus contingent value rights, which expired on December 8, 2025.
Why It Matters
Eli Lilly's acquisition of Adverum through a tender offer impacts stock valuations and investor sentiment, signaling strategic growth and potential future earnings tied to milestone achievements.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Adverum Biotechnologies has mailed a letter to stockholders regarding its pending acquisition by Eli Lilly, as it pioneers intravitreal gene therapy for sight preservation.
Why It Matters
Adverum's acquisition by Eli Lilly may enhance its valuation, streamline operations, and provide financial backing for its gene therapy, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Eli Lilly's acquisition of Adverum Biotechnologies (NASDAQ: ADVM), offering $3.56 per share plus contingent value rights worth up to $8.91.
Why It Matters
The investigation into Adverum's sale may indicate potential undervaluation or risks in the transaction, impacting shareholder sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Adverum Biotechnologies is set to be acquired by Eli Lilly for $3.56 per share in cash, plus a contingent value right potentially worth up to $8. The sale is under investigation by KSF.
Why It Matters
The investigation into the Adverum sale may signal potential legal issues, affecting stock performance and investor confidence regarding the deal's completion and value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Eli Lilly will acquire Adverum Biotechnologies for up to $261.7 million to enhance its pipeline with a treatment for an experimental eye disease.
Why It Matters
Eli Lilly's acquisition of Adverum Biotechnologies enhances its portfolio in gene therapy, potentially boosting growth prospects and market competitiveness in the biotech sector.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Monteverde & Associates is investigating Adverum Biotechnologies (NASDAQ: ADVM) in relation to its sale to Eli Lilly. The firm has a strong track record in shareholder recovery.
Why It Matters
The investigation into Adverum Biotechnologies' sale could signal potential legal troubles, impacting stock performance and shareholder confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ADVM Stock
What is Adverum Biotechnologies, Inc.'s (ADVM) stock forecast for 2027?
Based on our analysis of 14 Wall Street analysts, Adverum Biotechnologies, Inc. (ADVM) has a median price target of $5.00. The highest price target is $5.50 and the lowest is $4.00.
Is ADVM stock a good investment in 2027?
According to current analyst ratings, ADVM has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADVM stock?
Wall Street analysts predict ADVM stock could reach $5.00 in the next 12 months. This represents a 14.7% increase from the current price of $4.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adverum Biotechnologies, Inc.'s business model?
The company focuses on creating durable, single-administration gene therapies to treat serious ocular conditions. By utilizing an innovative vector platform for therapeutic gene delivery, it aims to address unmet medical needs in patients suffering from retinal diseases, thereby generating revenue through the development and commercialization of its therapeutic products.
What is the highest forecasted price for ADVM Adverum Biotechnologies, Inc.?
The highest price target for ADVM is $5.50 from at , which represents a 26.1% increase from the current price of $4.36.
What is the lowest forecasted price for ADVM Adverum Biotechnologies, Inc.?
The lowest price target for ADVM is $4.00 from Lisa Walter at RBC Capital, which represents a -8.3% decrease from the current price of $4.36.
What is the overall ADVM consensus from analysts for Adverum Biotechnologies, Inc.?
The overall analyst consensus for ADVM is neutral. Out of 14 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are ADVM stock price projections?
Stock price projections, including those for Adverum Biotechnologies, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2026 12:19 AM UTC